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Abstract
At present, there is no treatment modality for the vast majority of patients 
with dry AMD. The pathophysiology of AMD is complex but current evidence 
suggests that abnormal ageing of Bruch’s membrane imparts a metabolic insult to 
the retinal pigment epithelium (RPE) and photoreceptor cells that leads eventu-
ally to the inflammatory-mediated death of these cells. Underlying mechanisms 
contributing to the pathology of Bruch’s membrane include the accumulation of 
‘debris’ and malfunction of the matrix metalloproteinase (MMP) system result-
ing in diminished metabolic support of the retina and inefficient removal of toxic 
pro-inflammatory mediators. Saponins are amphipathic molecules that have a 
hydrophobic tri-terpenoid lipid region and hydrophilic glycosidic chains that allow 
for the dispersion of these deposits in Bruch’s and re-activation of the MMP system 
leading to a 2-fold improvement in the transport properties of the membrane. Such 
an intervention is expected to improve the bi-directional exchange of nutrients and 
waste products, thereby slowing the progression of dry AMD. This will be the first 
drug-based interventionist possibility to address dry AMD.
Keywords: macular degeneration, Bruch’s membrane, extracellular matrix, ageing, 
saponins
1. Introduction
Blindness due to AMD is of great concern to the ageing elderly population since 
the prevalence of the disease in Europe, in those aged 60 years and over has been 
estimated to be 27.7% with a projected increase in numbers from 67 to 77 million 
by 2050 [1]. Clinically, AMD is broadly divided into early, intermediate and late 
(or advanced) forms. Early AMD is characterised by the presence of large drusen 
and pigmentary abnormalities such as hypo- or hyperpigmentation of the fundus. 
Progression to the late form results in geographic atrophy of the RPE followed by 
photoreceptor degeneration, known as ‘dry’ AMD. The late phase is also associ-
ated with secondary complications of neovascular episodes (comprising 10-20% 
patients), these being designated as ‘wet’ AMD.
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The wet form of the disease can lead to rapid visual loss and considerable efforts 
at intervention have resulted in anti-vascular endothelial growth factor (anti-
VEGF) intra-vitreal injections with a considerable degree of success in managing 
the neovascularisation, but the underlying progression of the disease is not altered. 
Thus, the vast majority of AMD patients (falling in the ‘dry’ AMD category) still 
await the development of a suitable treatment modality that can either slow or 
arrest the progression of the disease [2, 3].
The pathophysiology of AMD is highly complex due to the diverse genetic asso-
ciations and considerable gene-environmental interactions exacerbated by the addi-
tional association of dietary and cardiovascular risk factors [4–6]. Furthermore, 
all these factors are superimposed on the normal ageing changes in the visual unit 
making it very difficult to nominate specific targets for intervention. Since age is the 
highest risk factor for the development of AMD, an understanding of the inherent 
stresses in the visual system would allow us to predict the likely effect of additional 
risk factors providing a more targeted approach towards therapy.
Briefly, in the visual unit, the photoreceptor is the primary site of sustained 
damage producing highly toxic compounds that can trigger an inflammatory 
response. However, this damage is rapidly transferred to the RPE by the daily shed-
ding of outer segment discs and phagocytosis. Since the RPE also operates in the 
same oxidative environment as the photoreceptor cell, the engulfed discs undergo 
further damage resulting in compromised lysosomal degradation. Non-degradable 
material, comprising mainly lipofuscin-related products is either packaged and 
stored in the RPE or extruded as membraneous debris onto Bruch’s membrane. 
With age, this debris accumulates in Bruch’s compromising its ability to transport 
nutrients, anti-oxidants, and vitamins essential for RPE and photoreceptor func-
tion. The toxic metabolites in Bruch’s are pro-inflammatory mediators and in the 
normal elderly, lead to a low-grade inflammatory response [7]. In advanced ageing 
associated with AMD, a chronic inflammatory response is precipitated leading to 
the death of RPE and photoreceptors.
For therapeutic intervention to be effective, the functional aspects of the RPE 
and Bruch’s membrane need to be restored. We will examine the compositional and 
functional alterations of ageing RPE and Bruch’s membrane, nominate suitable 
targets for intervention, and assess the potential for amphipathic saponin molecules 
to reverse these ageing changes as a potential therapy for dry AMD.
2.  Underlying stresses in the visual unit leading to ageing and 
pathophysiology
Photoreceptor physiology is dependent on the supportive roles provided by the 
RPE and Bruch’s membrane. Inherent stresses in these compartments lead to mor-
phological and functional deterioration manifesting as ‘normal’ ageing changes but 
in the advanced ageing scenario of AMD culminate in the transition to pathology. 
The stresses within each compartment of the visual unit will be identified, provid-
ing therapeutic targets for intervention.
2.1 Stresses generated in photoreceptor cells
The photoreceptor is a highly specialised neuronal cell capable of detecting a 
single photon of light. Absorption of light by rhodopsin (R) present in the outer 
segment disc membranes leads to isomerization of the 11-cis retinal chromophore 
to its all-trans form (AT-RL), producing activated rhodopsin (R*). Amplification 
of the light signal begins by rapid lateral diffusion of R* over the disc membrane 
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and interaction with many transducin molecules. Such high mobility of R* requires 
a very fluid membrane conferred by the high level of unsaturated docosahexanoic 
acid (DHA) in its membrane phospholipids. Further enzymatic amplification 
of the light signal by the guanalate cyclase-phosphodiesterase system leads to 
closure of sodium channels in the outer segment membrane resulting in hyper-
polarisation of the cell and concomitant modulation of transmitter release. To 
meet the energy demands of these processes, the photoreceptor maintains the 
highest rates of oxidative metabolism of any cell in the body. Associated with this 
activity is the release of damaging oxygen radicals by the mitochondrial electron 
 transport chain.
The presence of toxic retinoids, highly unsaturated fatty acids, high oxygen ten-
sion, high oxidative metabolism, and light is an explosive mixture for the generation 
of free-radical mediated damage. Since released AT-RL is highly toxic, it is rapidly 
reduced to all-trans retinol. However, AT-RL can react with phosphatidylethanol-
amine to form retinylidene-phosphatidylethanolamine (NRPE) [8]. NRPE can 
react with a second molecule of AT-RL to form a bis-retinoid. Further modifications 
produce a variety of all-trans retinal dimers including A2E, the auto-fluorescent 
fluorophore of lipofuscin [9]. These bis-retinoids can undergo photo-oxidation to 
form oxo-aldehydes which then react with proteins to form advanced glycation end-
products (AGEs) that are triggers of inflammatory processes [10].
Peroxidation of polyunsaturated fatty acids such as DHA results in fragmenta-
tion of the molecule leading to a mixture of compounds that bind to proteins 
[11, 12]. Oxidation of DHA produces carboxy-ethyl-pyrrole (CEP)-protein adducts. 
Thus, oxidation of PUFAs results in lipid aggregates, lipid-protein complexes, pro-
tein cross-link formation and CEP-adducts. These CEP-adducts have been localised 
to the RPE and drusen and being strongly immunogenic, activate the immune 
system [13].
Some protection from oxidative damage is afforded by the impressive anti-
oxidant machinery (vitamins C&E, macular pigments, and enzymes such as 
catalase, peroxidase, and superoxide dismutase) [14, 15]. However, this protection 
in photoreceptors is dependent on an adequate supply of anti-oxidants and essential 
metals for the enzymic system by the RPE and Bruch’s membrane. Despite these 
protective mechanisms, considerable damage is sustained by photoreceptors. 
Fortunately for the photoreceptor, this damage is confined to the outer segment 
discs and transferred to the RPE.
Therapeutic intervention to combat this damage has been considered resulting 
in the Age-Related Eye Disease Study (AREDS) vitamin and anti-oxidant supple-
ments and their effectiveness will be discussed later.
2.2 Oxidative damage in the RPE
The RPE operates in the same oxidative environment as the photoreceptor cell 
and therefore, the toxic reactions initiated in the outer segments will continue in 
the phagolysosome. Lysosomal enzymes hydrolyse the normal, undamaged protein 
and lipid components. recycling the base metabolites back to the photoreceptor cell. 
Damaged proteins, lipid-derived adducts, protein cross-links due to lipid-carbonyl 
attack, and aggregated lipid complexes that are no longer susceptible to lysosomal 
enzymes remain in the phago-lysosomal sac [16]. The lysosomal hydrolysis of 
bis-retinoids results in the formation of the primary age pigment, A2E. A2E and 
other bis-retinoids undergo further oxidation to produce a variety of toxic products 
that not only damage lysosomal enzymes but also damage the lysosomal membrane 
inhibiting the proton pumps with the subsequent increase in pH that will further 
diminish lysosomal enzyme activity [17].
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Un-hydrolysed lipoprotein and aggregated protein complexes together with 
bis-retinoids are packaged and stored as the auto-fluorescent pigment lipofuscin 
in membrane enclosed sacs. Lipofuscin content of the RPE increases with age and 
can amount to nearly 20% of cytoplasmic volume in the elderly [18]. Increased 
oxidative stress is inferred from the accumulation of AGEs in both ageing RPE and 
Bruch’s membrane [19]. The RPE has a battery of anti-oxidants and a robust enzy-
mic machinery to neutralise the oxidative stress and again, the components of the 
protective machinery are supplied by transport across Bruch’s membrane. However, 
the age-related accumulation of bis-retinoids and damaged proteins suggests that 
the anti-oxidant system is not effective in tackling this threat.
The primary functions of the RPE are (a) phagocytosis of shed outer segment 
discs and their degradation, (b) vectorial transport of nutrients, lipids, metals, vita-
mins and anti-oxidants, and the removal of waste products generated in the photo-
receptor cell, and (c) fluid transport from the sub-retinal space to the choroid. The 
effect of the age on the various functional parameters of the RPE are poorly under-
stood. One report has suggested that phagocytic activity is halved between the ages 
of 30 and 80 years [20]. Another important function of the RPE is the delivery 
of nutrients, anti-oxidants, vitamins, etc supplied by the choroidal circulation to 
the photoreceptor cell. Since the RPE is the site of the outer blood-retinal barrier, 
all metabolites must cross the interior of the cell to gain access to photoreceptors. 
Therefore, transport across the RPE is mediated by passive diffusion or facilitated 
by active and passive carriers in the membrane. Most active carriers utilise the 
sodium electro-chemical gradient generated primarily by mitochondrial respiration 
[21]. However, A2E generated in the RPE binds to cytochrome C of the electron 
transport chain impairing mitochondrial respiration and this is expected to impact 
on the effectiveness of active carrier transport [22, 23].
There is little information of the effect of age on the activity of ligand carriers of 
the RPE due largely to interference from the adjacent Bruch’s membrane. This is best 
illustrated with the transport of retinol (vitamin A). In elderly subjects and patients 
with early AMD, the recovery in dark-adaptation following a strong bleach is 
delayed [24, 25]. This delay is thought to be due to low levels of retinoids in the RPE 
and therefore slower transfer of 11-cis retinal to photoreceptors for regeneration of 
rhodopsin. Lowered levels of retinoids in the RPE could be due to lowered uptake by 
the RPE itself or diminished transport of retinol across Bruch’s membrane. The fact 
that there is improvement in dark-adaptation following vitamin A supplementation 
would suggest inefficient delivery across Bruch’s, rather than reduced uptake by the 
RPE as the contributary factor [26].
Fluid transport is another important function carried out by the RPE. Retinal 
fluids (originating from retinal capillary beds and retinal metabolism) are trans-
ported out by the RPE predominantly by an active process [27, 28]. The daily output 
of fluid from the RPE has been determined to be about 0.13 ± 0.11 μl/hour/mm2 and 
metabolic insufficiency in the RPE would lead to fluids accumulating on top of the 
RPE resulting in macular oedema and/or retinal detachment [29, 30].
Therapeutic intervention in support of the RPE would require effective delivery 
of anti-oxidants and strengthening of its metabolic capability so as to reduce the 
generation of toxic products and assist in their rapid removal.
2.3 Compositional changes in ageing Bruch’s membrane
Bruch’s membrane mediates the exchange of nutrients and waste products 
between the choroidal blood supply and the RPE. An age-related compromise in 
these functions will reduce the capacity to supply essential nutrients to the RPE and 
photoreceptor cells increasing the risk of damage in these compartments.
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The most obvious morphological change in Bruch’s with age is increased 
thickness from about 1.5 μm in the young to 5.5 μm in the elderly [31]. This is due 
primarily to the deposition of normal and abnormal extracellular matrix (ECM) 
material. In the elderly, cross-linked and denatured (damaged) collagen accounts 
for nearly 50% of total collagen in Bruch’s membrane [32]. There is also an increase 
in oxidative and non-enzymic glycosylation of proteins and lipids leading to the 
accumulation of toxic advanced glycation end-products, AGEs [33]. The membrane 
also shows an exponential increase in the level of lipid-rich debris [34]. Most of 
this debris arises from inefficient phagocytic processing of damaged outer segment 
discs in the RPE that is then extruded onto Bruch’s membrane. This material then 
undergoes further oxidative modification with both the inherent matrix proteins 
and with passer-by constituents leading to further damage and deposition. Finally, 
the lipid components undergo free-energy driven aggregation leading to the accu-
mulation of 100 nm diameter lipid-rich particles observed in the inner collagenous 
layer of Bruch’s membrane [35].
Thus, in addition to the toxic metabolites mentioned above, deposits in Bruch’s 
contain phospholipids, triglycerides, cholesterol, cholesterol esters, peroxidised 
lipids and apolipoproteins, immunoglobulins, amyloid, complement, and proteins 
specific to RPE function [36]. Heavy metal deposition has also been demonstrated 
that stabilises the debris in Bruch’s [37].
The above changes result in gross morphological alteration of ageing Bruch’s 
membrane that are expected to be detrimental to its transport functions (Figure 1).
Mechanisms exist to counteract the deleterious changes described above for 
Bruch’s membrane. This involves the continuous synthesis and degradation of the 
extracellular matrix, the latter process being mediated by the matrix metallopro-
teinase (MMP) system [38]. Although this system performs well in the young, it 
deteriorates rapidly with age and more so in AMD [39].
2.4 Functional deterioration of ageing Bruch’s membrane
Since Bruch’s membrane is crucial for the exchange of nutrients and waste prod-
ucts, a deficiency in its transport functions will increase the risk of damage in the 
RPE and photoreceptor compartments for the reasons outlined earlier. The extent to 
which the compositional alterations of ageing Bruch’s impact on its ability to remove 
Figure 1. 
Morphology of ageing Bruch’s membrane. With age, Bruch’s becomes thicker and contains a lot of debris rich 
in lipids, and abnormal matrix and non-matrix material. The increase in thickness alone will reduce the 
diffusional gradients for the transport of nutrients and waste products. Vertical bar denotes the thickness 
of Bruch’s membrane. ICL, inner collagenous layer, EL, elastin layer; OC, outer collagenous layer. Bar 
marker: 1 μm.
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fluids into the choroidal circulation, to supply adequate levels of essential nutrients, 
antioxidants, and vitamins to the RPE and photoreceptors, to maintain the rejuve-
nation potential of its membrane, and to modulate the occurrence of inflammatory 
responses will now be examined in both normal ageing and in the advanced ageing 
scenario of AMD.
2.4.1 Diminished fluid transport
The capacity for fluid transport across a membrane is designated by its hydraulic 
conductivity. As previously indicated, the daily output of fluid from the RPE and 
onto Bruch’s membrane is about 0.13 ± 0.11 μl/hour/mm2. To effectively transport 
this amount of fluid, Bruch’s needs to have a minimum hydraulic conductivity of 
0.65 x10−10 m/s/Pa, and this level is referred to as the failure threshold [40, 41]. If 
hydraulic conductivity falls below this level, then fluid will accumulate on top of the 
membrane leading to a RPE detachment. Hydraulic conductivity of human Bruch’s 
has been determined in 56 donors spanning the age range 1-91 years (Figure 2, 
modified from reference [40]). Conductivity was shown to decline exponentially 
with age and in the semi-log plot, the transformation is shown as a straight line. The 
half-life of the decay process was 16 years, i.e., conductivity was halved for every 
16 years of life. Excess capacity is present in the younger population but with age, 
there is a drift towards the failure threshold. Extrapolating the straight line shows 
that the shelf-life of human Bruch’s is about 123 years, but in the data of Figure 2, 
two of the normal donors have already reached the failure threshold. Bruch’s from 
AMD donors showed a faster rate of decline in hydraulic conductivity [40] and as 
such, complications of RPE detachment are observed in about 12-20% of AMD 
patients [42].
For an effective therapeutic intervention in AMD, the exponential decay line in 
Figure 2 needs to be elevated so as to avoid the failure threshold within the life-time 
of an individual.
Figure 2. 
Semi-logarithmic plot to show the exponential decay in the hydraulic conductivity of human Bruch’s with age. 
(Modified from reference [40]).
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2.4.2 Diminished metabolite and waste transport
Metabolites ranging from the simple sugars and amino acids to the much larger 
lipo-protein complexes are released from the fenestrated endothelium of the cho-
riocapillaris vessels and traverse Bruch’s by passive diffusion. Most of the essential 
metabolites such as heavy metals, vitamins (including vitamin A), and lipids are 
transported bound to carrier proteins that generally have a hydrodynamic radius of 
about 3-12 nm.
To assess the effect of age on the diffusional status of human Bruch’s mem-
brane, a FITC-albumin test probe was utilised that has a hydrodynamic radius 
of about 3.5 nm, similar to most carrier proteins. Diffusional experiments were 
conducted in standard Using chambers utilising isolated Bruch’s membrane prepa-
rations from 33 donors, age range 12-92 years. The diffusional status of Bruch’s 
membrane was observed to decrease exponentially with age, with a half-life of 18 
years (Figure 3) [43]. Thus, over a human life-span, diffusional status was reduced 
by about 10-fold. We do not know the value of the failure threshold for diffusion 
across Bruch’s membrane. However, since most elderly subjects show delayed dark-
adaptation due to inefficient transport of vitamin A, the albumin diffusion values 
of subjects aged 77-87 years (0.024 nmol/6 mm/hour) were taken as the failure 
threshold.
Other in-vitro studies utilising serum proteins (MW 40-200 kDa) or FITC-
dextran molecules (MW 21 kDA, radius 3.3 nm) have also shown a >10-fold reduc-
tion in diffusion capability over a human life-span [44, 45].
In AMD, the reduction in diffusional transport across Bruch’s membrane was 
much more severe compared to age-matched controls [45]. This reduction in 
transport is expected to impact on the nutritional and anti-oxidant support of both 
RPE and photoreceptor cells, increasing oxidative stress. Similarly, transport in the 
opposite direction i.e., removal of toxic waste products from Bruch’s membrane 
will also be diminished leading to greater oxidative modifications and generation of 
further toxic products.
As with hydraulic conductivity, for effective therapeutic intervention, the dif-
fusional decay curves should be elevated away from the failure threshold.
Figure 3. 
The effect of age on the diffusion of albumin across human Bruch’s. Semi-logarithmic plot showing the decay 
half-life to be 18 years.
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Reduced diffusion within Bruch’s membrane will also affect the protective 
mechanisms that depend on rapid mobility such as the interactions of complement 
factor H (CFH) with its many ligands and activation of pro-MMP2 in the regenera-
tion of Bruch’s. These aspects are described below.
2.4.3 Impaired regeneration in ageing Bruch’s membrane
The ECM of Bruch’s is continuously regenerated by coupled processes of 
synthesis and degradation. This ensures that damaged material is removed and 
replaced by new ECM components synthesised by the RPE, thereby maintaining 
the transport integrity of Bruch’s membrane. Since abnormal collagen accumulates 
in ageing Bruch’s (amounting to 50% of total collagen in the elderly), the regenera-
tion process appears to be dysfunctional [32]. Little is known about the synthetic 
rate of ECM by the ageing RPE but the accumulation of damaged ECM components 
suggests problems with the degradation machinery.
Matrix degradation is mediated by a family of proteolytic enzymes called the 
matrix metalloproteinases (MMPs). These are synthesised in the RPE and released 
into Bruch’s membrane as latent pro-enzymes (pro-MMPs) that on activation, fol-
lowing the removal of a small inhibitory peptide, can degrade almost all components 
of the ECM [38, 46]. In Bruch’s, the major MMP species are pro-MMP2 and pro-
MMP9, the former being the homeostatic enzyme in the system and the latter being 
the inducible form. Activation of pro-MMP2 occurs on the basolateral surface of 
the RPE by the initial formation of a binary complex between the membrane bound 
MMP-14 and the tissue inhibitor of MMPs, TIMP2. This then binds pro-MMP2 to 
form a tertiary complex that then results in the hydrolysis of the inhibitory peptide 
on pro-MMP2 by a second molecule of MMP-14, to release activated MMP-2 [47].
Thus, optimal pro-MMP2 activation requires adequate levels of pro-MMP2 and 
TIMP2 and good mobility of these two components within the matrix of Bruch’s 
to interact with the MMP-14 enzyme on the RPE basal membrane. The age-related 
reduction in diffusion within Bruch’s is expected to compromise this activation 
potential (Figure 3). Furthermore, pro-MMP2 covalently binds pro-MMP9 to 
form the high molecular weight complex termed HMW2, reducing its level for the 
activation process [48]. A polymorphism in the microsatellite region of the MMP9 
gene (present in most AMD patients) results in elevated levels of pro-MMP9 in both 
plasma and Bruch’s membrane, increasing the potential for further sequestration of 
pro-MMP2 from the activation step [39, 49–51].
The gross alterations of ageing Bruch’s membrane together with the reduction 
in diffusional competence are expected to hamper the mobility of pro-MMP2 and 
TIMP2, diminishing the activation of this MMP. Thus, levels of activated MMP2 
decrease with age, and in AMD, the level was reduced by 50% compared to age-
matched controls [39]. It should also be noted that activated MMP2 may not be able 
to diffuse adequately to interact with its substrate and in the gross morphology of 
Figure 1, may be trapped within the membrane. The decreased turnover of Bruch’s 
leads to the deleterious morphological and functional changes described earlier 
culminating in diminished support of RPE and photoreceptors.
2.4.4 Ageing and increased susceptibility to inflammatory intervention
Many of the toxic products produced in the RPE and present in Bruch’s (as 
outlined earlier), including A2E, bis-retinoids, malonaldehyde, carbonyl lipids, 
C-reactive protein, etc., are capable of activating the complement system [52]. 
Thus, in elderly subjects, the exponential increase in A2E in Bruch’s may be associ-
ated with a low-grade complement activation [53, 54]. A low-grade inflammatory 
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response may be beneficial for eliminating toxic metabolites present in Bruch’s or 
in drusen and may serve to prevent the transition from normal ageing to pathol-
ogy. Thus, the presence of the membrane attack complex and other complement 
factors in drusen and inter-capillary columns may allow their removal by macro-
phages [55].
However, indiscriminate activation of the complement system can lead to a 
chronic inflammatory response damaging RPE and photoreceptor cells. CFH (a 
155 kDa glycoprotein) plays important roles in modulating the activation of the 
complement cascade. Firstly, it can bind to the toxic entities to prevent complement 
activation and secondly, by binding to the C3b complement component, block the 
progression of the cascade [56–58].
Levels of CFH in Bruch’s are maintained by synthesis in the RPE and binding 
to glycosaminoglycans in the membrane, and delivery of plasma-derived CFH. 
With age, and under oxidative stress, the production of CFH by the RPE is reduced 
[59, 60]. Similarly, the nearly 10-fold decrease in diffusion across elderly Bruch’s is 
expected to compromise delivery from the blood. Furthermore, in the presence of 
inflammatory activity in Bruch’s, CFH is nitrated [61]. This nitrated CFH does not 
bind lipid peroxidation products nor C3b, diminishing its protective ability. Also, 
plasma levels of nitrated CFH are elevated in AMD patients and this may contribute 
to AMD progression [61].
A polymorphism in the CFH gene (Tyr402His) has been detected in about 50% 
of AMD patients [62, 63]. This mutated CFH shows diminished binding to toxic 
ligands such as malondialdehyde and C-reactive protein, and thus becomes ineffec-
tive in modulating the inflammatory response [64–66]. Mutated CFH also shows 
poor binding to heparin sulphate in Bruch’s and hence its enhanced presence in 
Bruch’s is compromised [67].
Ageing changes in Bruch’s and the RPE therefore compromise the protective 
effects of CFH and in the aged AMD patient may exacerbate the inflammatory 
response leading to the death of RPE and photoreceptors.
3. Requirements for effective therapeutic intervention in dry AMD
Oxidative damage in the RPE and Bruch’s membrane is the primary driver of 
ageing changes in the normal elderly and more so in patients with AMD. These 
ageing changes diminish the supply of key anti-oxidants and vitamins required 
to combat oxidative stress and therefore a vicious cycle is set-up that leads to the 
degenerative changes in AMD.
Anti-oxidant and vitamin supplement regimes have been devised as a possible 
interventionist measure to reduce oxidative stress and hopefully slow the progres-
sion of the disease. Thus, the AREDS dietary supplementation cocktail was devised 
(vitamin C (500 mg), vitamin E (400 IU), beta-carotene (15 mg), zinc oxide (80 
mg), and cupric oxide (2 mg)) and initial results showed it to be effective in reduc-
ing the risk of visual loss [68, 69]. The supplement was further modified (as the 
AREDS 2 formulation) by removing beta-carotene and adding lutein (10 mg) and 
zeaxanthine (2 mg) but did not confer any additional benefits [70].
Despite the wide use of AREDS supplements for over 10 years, controversy 
remains as to its usefulness since it does not prevent legal blindness in advanced 
AMD [71]. It has been pointed out that the earlier reported decrease in progression 
was related to the occurrence of neovascularisation rather than slowing the progres-
sion of dry AMD [72].
Given the fact that the diffusion of metabolites across Bruch’s membrane is 
reduced by nearly 10-fold in the elderly, and perhaps more so in AMD, one must 
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question the likely effectiveness of such dietary supplementation. The major 
problem with supplementation therapies is that they do not address transport in the 
opposite direction across Bruch’s membrane i.e., the removal of toxic metabolites 
that are the likely triggers of neovascular and inflammatory episodes.
For effective therapeutic intervention, it would be ideal to improve the bi-direc-
tional transport pathways across Bruch’s membrane, to improve nutritional and 
anti-oxidant delivery and to remove toxic waste products. This would require the 
destabilisation and dispersal of the lipid-rich debris and the removal of normal and 
damaged proteinaceous deposits. Such a strategy would also release trapped acti-
vated MMP enzymes that could participate in hydrolysing the altered collagenous 
components. The expected improvement in intra-membrane mobility would favour 
greater activation of pro-MMP2, kick-starting the normal rejuvenation machinery 
in Bruch’s membrane. Therapeutic success would be realised if the transport decay 
curves shown in Figures 2 and 3 could be elevated so that they no longer crossed the 
failure threshold within the lifetime of an individual. The potential implementation 
of such a strategy using saponin molecules is discussed next.
4.  Saponin characteristics enabling therapeutic intervention  
in dry AMD
Saponins are amphipathic molecules that have hydrophobic and hydrophilic 
domains that can partition into lipoidal deposits and assist dispersal [73–76]. 
Saponins extracted from the ginseng plant (Panax ginseng CA Meyer) have a 
4-membered triterpenoid ring and are often referred to as ginsenosides or ste-
roidal glycosides because of the structural similarity to the cholesterol molecule 
(Figure 4A). The type and number of sugar units attached at sites R1, R2, and R3 
Figure 4. 
Saponins extracted from the ginseng plant. (A) Structural similarity of saponins to the cholesterol molecule. 
Sugar attachment sites R1, R2, and R3 lead to the diversity of saponin species. (B) TLC of extracted saponins. 
G1 to G11 denote the major spots, each spot comprising several species.
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gives rise to a myriad of species and over 30 have been structurally characterised. 
Saponins extracted from the roots of the ginseng plant were separated on Silica 
Gel thin-layer-chromatography (TLC) plates using a solvent mixture comprising 
chloroform: methanol: acetic acid: water (50:30:8:3 v/v) and colour developed by 
spraying with 20% sulphuric acid in methanol and heating to 100 oC for 5 minutes 
(Figure 4B). Since the separation was dependent on the degree of hydrophilic/
hydrophobic properties, each spot on the chromatogram represents a collection of 
several species.
These saponin molecules not only bind to various lipid classes, they also display 
transition metal chelating properties [77, 78]. Thus, saponins can chelate the heavy 
metal deposits in Bruch’s membrane and therefore assist in destabilising the lipid 
aggregates.
4.1 Saponin mediated dispersal of lipid deposits
The potential for saponin mediated dispersal of lipids was assessed in both 
isolated deposits and intact human Bruch’s membrane. Bruch’s from four donor eyes 
(ages 50 and 82 years) was homogenised in Tris-buffer and spun to obtain pellets 
containing the deposits. Pellets were resuspended in Tris buffer containing ginseng-
derived saponins in the range 0-1.2 mg/ml and incubated for 12 hours at 37oC. 
Samples were then spun and any lipids released into the supernatants extracted 
with chloroform: methanol (2:1 v/v). Lipids were then separated on Silica Gel thin-
layer chromatography (TLC) plates using solvent system #1, chloroform: methanol: 
acetic acid: water (50:30:8:3 v/v) and solvent system #2, heptane: diethyl ether: 
acetic acid (70:30:2 v/v). Lipid spots were visualised by staining with amido-black 
10B stain and following densitometry, levels quantified with reference to standard 
curves. Saponins were observed to rapidly release various lipid classes from the 
deposits in a dose dependent manner (Figure 5).
In addition, 14 Bruch’s preparations were obtained from 4 human donors (age 
range 64-75 years) and mounted in Ussing chambers. All chambers were perfused 
with Tris buffer to remove loosely attached debris and then half the chambers were 
incubated with Tris buffer and the other half with Tris buffer containing 4.6 mg/ml 
saponins for 12 hours at 37oC. Chambers were rinsed in Tris buffer and the content 
of the various lipid classes present in Bruch’s membrane quantified as detailed 
above. The content of lipids in the samples incubated with saponins was signifi-
cantly reduced compared to controls (Figure 6). Thus, saponin molecules are able 
to solubilise and disperse the lipid deposits in Bruch’s membrane.
4.2 Saponin-mediated release of deposited proteins
Soluble proteins that are either damaged due to chemical modification or dena-
tured tend to unfold exposing the hydrophobic regions to the aqueous environment. 
This leads to aggregation and deposition within Bruch’s membrane. The possibility 
that saponins could interact with these ‘amphipathic’ structures to de-segregate 
and solubilise them was also assessed. Bruch’s membrane from four human donors 
(age range 49-77 years) was mounted in 8 Ussing chambers and perfused with Tris 
buffer. The perfusate was collected every 5 hours and the protein content deter-
mined. As indicated in Figure 7, perfusion with Tris buffer resulted in slow release 
of loosely adherent proteins up to the fourth perfusion period (20 hours). In four 
chambers, the perfusion fluid was then switched to one containing 167 μg/ml of 
saponin Rb1. This resulted in the rapid and copious release of further, presumably 
trapped proteins from the membrane (Figure 7). The possibility that trapped MMP 
enzymes may also have been released is assessed below.
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Figure 5. 
Saponin-mediated release of lipids from deposits extracted from Bruch’s membrane. Extracted deposits were 
incubated with saponins in the range 0-1.2 mg/ml for 12 hours, spun, and lipids present in the supernatant 
quantified. Saponins released cholesterol, cholesterol esters, phospholipids, and triglycerides in a dose-dependent 
manner. Data is given as Mean ± SD.
Figure 6. 
Saponin-mediated release of lipids from intact human Bruch’s membrane. The level of the major lipid classes 
was reduced following saponin treatment. Data is given as Mean ± SD.
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Figure 7. 
Solubilisation and release of trapped proteins from Bruch’s membrane. On perfusion with saline, loosely 
adherent proteins are released slowly. When there was no further release (after period 4), the perfusion 
medium was switched to one containing Rb1, resulting in the copious release of trapped proteins. TBS-Tris 
buffered saline; Rb1-Ginsenoside Rb1. Data as Mean ± SD.
Figure 8. 
Saponin-mediated release of trapped MMP enzymes. (A) Perfusion with Tris buffer did not release any MMP 
species from Bruch’s membrane. (B) Saponin perfusion released trapped MMP species and in particular 
activated forms of MMPs 2&9. FCS-foetal calf serum standard. P- pro-MMPs; A-activated MMPs. From 
reference [43].
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4.3 Saponin-mediated release of trapped MMP enzymes
MMPs are detected by the technique of gelatine zymography. This is standard 
electrophoresis but with the gel containing 1% gelatine, a substrate for MMPs. 
Samples are electrophoresed with the MMPs migrating according to molecular 
weight, the smaller ones running fastest. Following electrophoresis, the gel is 
incubated in Tris-buffer (containing calcium) for a period of 18-24 hours to allow 
the MMP enzymes to digest the gelatine in their locality. The gel is then stained with 
Coomassie Blue and after de-staining, regions containing gelatine stain blue but 
where the gelatine has been hydrolysed (by MMP enzymes), the region is colour-
less. Reversing the grey-scale of the gel image shows the MMP regions as dark bands 
and the identity of the MMP is confirmed from its molecular weight.
To assess the likely effect of saponins on release of trapped MMP enzymes, 
Bruch’s membrane from donors aged 49-71 years was mounted in Ussing chambers 
and perfused for a period of 12 hours to remove plasma-derived and loosely bound 
MMP species. Half the chambers were then perfused with Tris buffer for three 
periods of 3 hours each and the remaining half with saponins at a level of 4.6 mg/
ml. After each period, the perfusate was collected and examined by zymography. 
Incubation with Tris did not show the release of any MMP species (Figure 8A). 
However, perfusion with saponins showed a trace release of MMPs in the first 
period followed by greater release in the two subsequent periods (Figure 8B). The 
release profiles showed the presence of activated MMP9 and MMP2. If this release 
occurred in vivo, it would kick start the MMP degradation machinery, rejuvenating 
the membrane.
5. Functional improvement of Bruch’s membrane
Saponins have been shown to disperse and release lipid deposits, protein aggre-
gates and trapped active MMP enzymes as described earlier. This is akin to reversing 
the ageing process of Bruch’s membrane. The likely impact of these changes on the 
functional properties of Bruch’s has also been assessed by monitoring hydraulic 
conductivity and diffusional status.
5.1 Hydraulic conductivity of saponin treated human Bruch’s
Hydraulic conductivity measurements were undertaken in 23 preparations of 
Bruch’s membrane from donors over the age range 13-90 years. After determining 
basal hydraulic conductivity, samples were incubated with saponins (4.6 mg/ml) 
for 24 hours at 37oC. After a thorough rinse in Tris buffer, the hydraulic conductiv-
ity was re-assessed. Treatment with saponins improved the hydraulic conductivity 
about 2-fold (p < 0.0001) elevating the exponential decay curves upwards, away 
from the failure threshold (Figure 9).
The curves were shifted by 19 years, reversing the ageing decline in fluid trans-
port. Such a shift means that the curves will meet the failure threshold outside the 
normal human life span. In AMD, this improvement will reduce the risk of pigment 
epithelial detachments that normally affects 12-20% of these patients. These results 
were obtained after a single exposure to the saponins. A second subsequent expo-
sure to the saponins (1.15 mg/ml) further increased the improvement in hydraulic 
conductivity indicative of potential to further elevate the decay curves (Figure 10). 
This is the likely result of continued removal of lipid and protein debris and release 
of MMP enzymes.
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5.2 Diffusional status of saponin treated human Bruch’s
Diffusional status of Bruch’s was assessed by following the transport of an FITC-
labelled albumin test molecule (MW 65 kDa, hydrodynamic radius 3.5 nm) across 
the membrane, at a concentration gradient of 0.1 mM. Bruch’s was obtained from 21 
human donors (age range 12-92 years) and the basal diffusion rate was first deter-
mined. After a thorough wash in Tris buffer for 3 hours to remove all traces of albu-
min, the samples were incubated with saponin solution (4.6 mg/ml) for 24 hours 
at 37oC. Following a rinse with Tris buffer, the diffusional status was re-assessed. 
Exposure to saponins improved the diffusional status of Bruch’s membrane by 
2-fold (p<0.0001) shifting the ageing decay lines upwards, effectively reversing the 
ageing process by ~15 years (Figure 11).
Figure 9. 
Effect of saponins on the hydraulic conductivity of human Bruch’s membrane. Saponins improved the hydraulic 
conductivity by 2-fold across the age range examined (p<0.0001). Decay curves were elevated so that failure 
threshold was met 19 years later. Modified from reference [43].
Figure 10. 
Effect of repeated saponin exposure on the hydraulic conductivity of Bruch’s membrane. Initial exposure to 
saponins improved hydraulic conductivity by over 2-fold. This was further increased by a second exposure.
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Saponin mediated improvement in diffusion within Bruch’s membrane would 
allow greater delivery of nutrients, vitamins and anti-oxidants to both the RPE and 
photoreceptor cells. Reduction in oxidative stress would result in reduced produc-
tion of A2E and other bis-retinoids minimising the generation of pro-inflammatory 
mediators. Similarly, the removal of toxic waste products from Bruch’s would be 
facilitated. This would also improve the mobility of TIMP2 and proMMP2 allowing 
greater activation of the MMP species and thus improved turnover of Bruch’s mem-
brane. Furthermore, improved mobility of CFH would minimise the risk of inflam-
matory involvement. In AMD, these changes are expected to slow the degenerative 
phase of the disease.
6. Conclusions: potential for saponin-mediated therapy in dry AMD
In-vitro work, using donor human Bruch’s preparations has demonstrated the 
potential for saponin molecules to disperse and remove lipoidal and proteinaceous 
debris, releasing trapped activated MMP enzymes that can then mediate the normal 
degradation processes essential for rejuvenation of the membrane. Associated with 
these changes was a significant improvement in the bi-directional transport proper-
ties of Bruch’s membrane. In vivo, improved transport would considerably aug-
ment the delivery of protective anti-oxidants and related nutrients to the RPE and 
photoreceptor cells and more importantly stimulate the removal of toxic products 
that underlie the progression of the disease.
Saponins constitute a large mixture of amphipathic molecules, the diversity 
being due to the varied nature of sugar residues at the several attachment sites 
on the aglycone ring structure. Individual species, such as ginsenoside Rb1 or 
Compound K have been shown to improve the functional status of Bruch’s mem-
brane preparations [43]. These compounds could be administered by intra-ocular 
injection as a potential therapy. But being very difficult to synthesise, reliance 
would have to be on isolation and purification from natural sources and therefore 
not likely to be cost-effective.
The alternative would be to utilise a varied mixture of saponins and this has 
many advantages. Firstly, they can be administered orally and in the Far East 
have been used as nutritional supplements for centuries. Secondly, and most 
Figure 11. 
Effect of saponins on the diffusional status of Bruch’s membrane. Saponin incubation improved diffusion 
(p<0.0001) elevating the decay curves upwards so that they reached failure thresholds 15 years later. Modified 
from reference [43].
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importantly, a mixture can target a broad spectrum of substrates that are normally 
encountered in the deposits in Bruch’s membrane. From the pharmacokinetic data 
currently available for saponins, and our in-vitro dose response curves, calculations 
suggest that a 200 mg dose of an appropriate saponin mixture, taken twice daily, 
should significantly improve the transport characteristics of Bruch’s membrane 
over a period of 4-6 months. Work is in progress to develop a clinical protocol for 
 assessing the usefulness of saponin-mediated therapy for dry AMD.
Unlike other therapeutic interventions in AMD where outcome has been judged 
by following the progression of the disease over a period of 2-5 years, the saponin 
intervention can be assessed at 4-6 months using dark-adaptation kinetics. Since 
the saponin intervention aims at improving the transport systems in Bruch’s 
membrane, the increased delivery of vitamin A would supplement the retinoid 
stores in the RPE allowing faster delivery of 11-cis retinal to the photoreceptor, and 
hence faster dark adaptation would be expected as proof of principle of saponin 
intervention.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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